Circulating miRNAs: Promising biomarkers of human cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 5, 2011, Pages 1117-1125

  Qu, Hongguang ^a   Xu, Weiwei ^a   Huang, Yuchuan ^b,c   Yang, Shujuan ^d  

^a Urumchi Friendship Hospital   (China)

^b China Tobacco Chuanyu Industrial Corporation   (China)

^c SICHUAN UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Biomarkers; Human cancers; miRNAs

Indexed keywords

EID: 84863229464     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (106)

1. Ambs S, Prueitt RL, Yi M, et al (2008). Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Res, 68, 6162-6170.
2. Ambros V, (2003). MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113, 673-676.
3. Bartel DP, (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
4. Bast Jr RC, Hortobagyi GN, (2004). Individualized care for patients with cancer-a work in progress. N Engl J Med, 351, 2865-2867.
5. Bentwich I, (2005). Prediction and validation of microRNAs and their targets. FEBS Lett, 579,5904-5910.
6. Bukowski RM, (1997). Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 80, 1198-1220.
7. Calin GA, Croce CM, (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6,857-866.
8. Calin G A, Dumitru C D, Shimizu M, et al, (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS, 99, 15524-15529.
9. Calin GA, Ferracin M, Cimmino A, et al, (2005). A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 353, 1793-1801.
10. Calin GA, Sevignani C, Dumitru CD, et al, (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS, 101,2999-3004.
11. Cannistra SA, (2004). Cancer of the ovary. N Engl J Med, 351, 2519-2529.
12. Chang JT, Katzka DA, (2004). Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med, 164, 1482-1488.
13. Feber A, Xi L, Luketich JD, et al, (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-260.
14. Chen CZ, Li L, Lodish HF, Bartel DP, (2004). MicroRNAs modulate hematopoietic lineage differentiation. Science, 303, 83-86.
15. Chen X, Ba Y, Ma L, et al, (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
16. Chim SS, Shing TK, Hung EC, et al, (2008). Detection and characterization of placental microRNAs in maternal plasma. Clin Chem, 54,482-490.
17. Chiorazzi N, Rai KR, Ferrarini M, (2005). Chronic lymphocytic leukemia. N Engl J Med, 352, 804-815.
18. Dahiya N, Sherman-Baust CA, Wang TL, et al, (2008). MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE, 3, 2436.
19. Duffy MJ, (2001). Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci, 38, 225-262.
20. Duffy MJ, (2007). Role of tumor markers in patients with solid cancers:a critical review. Eur J Intern Med, 18,175-184.
21. Esquela-Kerscher A, Slack FJ, (2006). Oncomirs: MicroRNAs with a role in cancer. Nat Rev Cancer, 6, 259-269.
22. Fahy BN, Bold RJ, Schneider PD, et al, (2001). Costbenefit analysis of biopsy methods for suspicious mammographic lesions. Arch Surg, 136, 990-994.
23. Feng G, Li G, Gentil-Perret A, et al, (2008). Elevated serumcirculating RNA in patients with conventional renal cell cancer. Anticancer Res, 28, 321-326.
24. Gamliel Z, Krasna MJ, (2005). Multimodality treatment of esophageal cancer. Surg Clin North Am, 85, 621-630.
25. Gottardo F, Liu CG, Ferracin M, et al, (2007). Micro-RNA profiling in kidney and bladder cancers. Urologic oncology, 25, 387-392.
26. Garzon R, Volinia S, Liu CG, et al, (2008). MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 111,3183-3189.
27. Gilad S, Meiri E, Yogev Y, et al, (2008). Serum microRNAs are promising novel biomarkers. PLoS ONE, 3,3148.
28. GuoY, Chen Z, Zhang L, et al, (2008). Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res, 68, 26-33.
29. Harris L, Fritsche H, Mennel R, et al, (2007). American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J ClinOncol, 25, 5287-5312.
30. Herling M, Patel K A, Khalili J, et al, (2006). TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia, 20,280-285.
31. Hewitson P, Glasziou P, Watson E, et al, (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test, (hemoccult): an update. American Journal of Gastroenterol, 103, 1541-1549.
32. Hoffman AE, Zheng TZ, Yi CH, et al, (2009). MicorRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res, 69, 5970-5977.
33. Huang Y, Dai Y, Yang J, et al, (2009). Microarray analysis of microRNA expression in renal clear cell carcinoma, 35, 1119-1123.
34. Iorio MV, Casalini P, Tagliabue E, et al, (2008). MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer, 44, 2753-2759.
35. Hoffman PC, Mauer AM, Vokes EE, (2000). Lung cancer. Lancet, 55,479-485.
36. Iorio MV, Visone R, Di Leva G, et al, (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-8707.
37. Laios A, O'Toole S, Flavin R, et al, (2008). Potential role of miR-9 and miR-233 in recurrent ovarian cancer. Molecular Cancer, 7,35.
38. Jemal A, Siegel R, Ward E, et al, (2008). Cancer statistics, 2008. CA Cancer J Clin,58,71-96.
39. Jacobs I, Davies AP, Bridge J, et al, (1993). Prevalence screening for ovarian cancer in post-menopausal women by CA-125 measurement and ultrasonography. BMJ, 306, 1030-1034.
40. Jacobs IJ, Menon U, (2004). Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics, 3, 355-366.
41. Jemal A, Siegel R, Ward E, et al, (2008). Cancer statistics. CA Cancer J Clin,58,71-96.
42. Ji JF, Shi J, Budhu A, et al, (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 361, 1437-1447.
43. Jiang J, Gusev Y, Aderca I, et al, (2008). Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 14, 419-427.
44. Kluiver J, Poppema S, de Jong D, et al, (2005). BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol, 207,243-249.
45. Kovacs G, (1993). Molecular differential pathology of renal cell tumours. Histopathology, 22, 1-8.
46. Krichevsky AM, Gabriely G, (2009). miR-21: a small multifaceted RNA. J Cell Mol Med, 13, 39-53.
47. Kutay H, Bai S, Datta J, et al, (2006). Downregulation of miR-122 in rodent and human hepatocellular carcinomas. J Cell Biochem, 99, 671-678.
48. Lawrie CH, Gal S, Dunlop HM, et al, (2008). Detection of elevated levels of tumor-associated microRNAS in serum of patients with diffuse large B-cell lymphoma. Br J Heametol,141,672-675.
49. Lebanony D, Benjamin H, Gilad S, et al, (2009). Diagnostic assay based on has-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin oncol, 27, 2030-2037.
50. Li J, Smyth P, Flavin R, et al, (2007). Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded, (FFPE) cells and snap-frozen cells. BMC Biotechnol, 7,36.
51. Marcucci G, Radmacher MD, Maharry K, et al, (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med, 358, 1919-1928.
52. Lodes MJ, Caraballo M, Suciu D, et al, (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE, 4, 6229.
53. Lowery AJ, Miller N, McNeill RE, et al, (2008). MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res, 14,360-365.
54. Lu J, Getz G, Miska EA, (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
55. Marcucci G, Radmacher MD, Maharry K, et al, (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med, 358, 1919-1928.
56. Mathe EA, Nauyen GH, Bowman ED, et al, (2009). MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res,15, 6192-6200.
57. Mitchell PS, Parkin RK, Kroh EM, et al, (2008). Circulating microRNAs as stable blood-based markers for cancer detection. PNAS, 105, 10513-10518.
58. Monzo M, Navarro A, Bandres E, et al, (2008). Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res, 18, 823-833.
59. Murakami Y, Yasuda T, Saigo K, et al, (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-turmorous tissues. Oncogene, 25, 2537-2545.
60. Myers ER, Bastian LA, Havrilesky LJ, et al, (2006). Management of adnexal masses. Evid Rep/ Technol Assess, 130, 1-145.
61. Nam EJ, Yoon H, Kim SW, et al, (2008). MicroRNA expressionprofiles in serous ovarian carcinoma. Clin Cancer Res, 14, 2690-2685.
62. Taylor DD, Gercel-Taylor C, (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 110, 13-21.
63. Nelson PT, Baldwin DA, Kloosterman WP, et al, (2006). RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA, 12, 187-191.
64. Ng EKO, Chong WWS, Jin H, et al, (2009). Differential expression of microRNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut, 58, 1375-1381.
65. Parkin DM, Bray F, Ferlay J, Pisani P, (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
66. Pekarsky Y, Santanam U, Cimmino A, et al, (2006). Tcl1 expression in CLL is regulated by miR-29 and miR-181. Cancer Res, 66, 11590-11593.
67. Pfeffer S, Zavolan M, Grasser FA, et al, (2004). Identification of virus-encoded microRNAs. Scienc, 304, 734-736.
68. Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al, (2005). rastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-1672.
69. Pui Ching-Hon, Robison L, A Thomas Look, (2008). Acute lymphoblastic leukaemia. Lancet, 371, 1030-1043.
70. Pohl H, Welch HG, (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst, 97, 142-146.
71. Porkka KP, Pfeiffer MJ, Waltering KK, et al, (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-6135.
72. Rabinowits G, Gerçel-Taylor C, Day JM, et al, (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer, 10, 42-46.
73. Rachet B, Woods LM, Mitry E, et al, (2008). Cancer survival in England andWales at the end of the 20th century. British Circulating miRNAs: Promising Biomarkers of Human Cancer Journal of Cancer, 99, S2-S10.
74. Raponi M, Dossey L, Jatkoe T, et al, (2009). MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res, 69, 5776-5783.
75. Reid BJ, Haggitt RC, Roessler S, Budhu A, Wang XW, (2007). Future of molecular profiling of human hepatocellular carcinoma. Future Oncol, 3, 429-439.
76. Resnick KE, Alder H, Hagan JP, et al, (2009). The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Genecol oncol, 1121, 5-59.
77. Rosell R, Wei J, Taron M, (2009). Circulating microRNa signature of tumor-derived exosomes for early diagnosis of non-smallcell lung cancer. Clin Lung Cancer, 10,8-9.
78. Roulston JE, (1990). Limitations of tumour markers in screening. Br Jsurg, 77,961-962.
79. Rubin CE, et al, (1988). Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol, 19, 166-178.
80. Schetter AJ, Harris CC, (2009). Plasma microRNAs: a potential biomarker for colorectal cancer? Gut, 58, 1318-1319.
81. Schetter AJ, Leung SY, Sohn JJ, et al, (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-436.
82. Sempere LF, Christensen M, Silahtaroglu A, et al, (2007). Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res, 67, 11612-11620.
83. Shen J, Ambrosone CB, DiCioccio RA, et al, (2008). A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-1966.
84. Shike M, Winawer SJ, Greenwald PH, et al, (1990). Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ, 68, 377-385.
85. Skog J, Wurdinger T, van RS, et al, (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 10, 1470-1476.
86. Society AC, (2008). Cancer Facts & Figures 2008. American Cancer Society Atlanta 2008.
87. Aslam MI, Taylor K, Pringle JH, Jameson JS, (2009). MicroRNAs are novel biomarkers of colorectal cancer. British Journal of Surgery, 96, 702-710.
88. Tanaka M, Oikawa K, Takanashi M, et al, (2009). Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PloS ONE, 4, e5532.
89. Thompson A, Brennan K, Cox A, et al, (2008). Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res, 10, R26.
90. Thorgeirsson SS, Grisham JW, (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Gen, 31, 339-346.
91. Thomas CM, Sweep CG, (2001). Serum tumor markers: past, state of the art, and future. Int J Biol Markers, 16,73-86.
92. Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther,16, 206-216.
93. Vasilatou D, Papageorgiou S, Pappa V, et al, (2010). The role of microRNAs in normal and malignat hematopoiesis. Eur J Haematol, 84, 1-16.
94. Volinia S, Calin GA, Liu CG, et al, (2006). A micro-RNA expression signature of human solid tumors defines cancer gene targets. PNAS, 103, 2257-2261.
95. Wang K, Zhang S, Marzolf B, et al, (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. PNAS, 106, 4402-4407.
96. Weir HK, Thun MJ, Hankey BF, et al, (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 95, 1276-1299.
97. Wong TS, Liu XB, Wong BY, et al, (2008). Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma ofTongue. Clin Cancer Res, 14, 2588-2592.
98. Yan X J, Albesiano E, Xi Y, et al, (2007). Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA, 13, 1668-1674.
99. Xu P, Vernooy SY, Guo M, et al, (2003). The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol, 13, 790-795.
100. Yanaihara N, Caplen N, Bowman E, et al, (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9,189-198.
101. Yan LX, Huang XF, Shao Q, et al, (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-2360.
102. Yang H, Kong W, He L, et al, (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-433.
103. Yang N, Kaur S, Volinia S, et al, (2008). MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res, 68,10307-1031.
104. Yi Z, Fu Y, Zhao S, et al, (2010). Differential expression of miRNA patterns in renal cell carcinoma and nonfumorous tissues. J Cancer Res Clin Oncol, 136, 855-862.
105. Zanesi N, et al, (2006). B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. PNAS, 103,11713-11718.
106. Zhu WZ, Qin WY, Atasoy U, et al, (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes, 2, 89.